Wird geladen...
Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report
A 61‐year‐old woman with stage IVA lung adenocarcinoma exhibited high PD‐L1 expression. Pembrolizumab was administered as second‐line therapy. She developed destructive thyroiditis and her thyroid function started to decline during the administration of three to five courses. She was subsequently di...
Gespeichert in:
| Veröffentlicht in: | Thorac Cancer |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley & Sons Australia, Ltd
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6500988/ https://ncbi.nlm.nih.gov/pubmed/30964601 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13065 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|